Pharmabiz

Lupin appoints Brian Savage as president, chief legal officer

Global pharma major Lupin Limited announced the appointment of Brian Savage as president, chief legal officer. Brian will lead Lupin’s global Legal, Compliance, and Intellectual Property Management ...
Pharmabiz

Supriya Lifescience joint MD Shivani Wagh featured on Avendus Wealth–Hurun India U35 List 2026

Supriya Lifescience joint MD Shivani Wagh featured on Avendus Wealth–Hurun India U35 List 2026: Our Bureau, Mumbai Saturday, October 24, 2026, 11:30 Hrs [IST] Supriya Lifescienc ...
Pharmabiz

Messe Muenchen India acquires PharmaTech Expo from PharmaTechnologyindex.com

Messe Muenchen India, a subsidiary of Messe München GmbH and a leading organiser of B2B trade fairs in India, has acquired PharmaTech Expo from PharmaTechnologyindex.com Pvt Ltd. (A Division of KNS ...
Pharmabiz

Prognica Labs and Pinnacology enter co-development and commercialization partnership to advance novel intranasal anxiety therapy

Prognica Labs and Pinnacology enter co-development and commercialization partnership to advance novel intranasal anxiety therapy: Dubai, UAE Saturday, October 24, 2026, 09:00 Hrs ...
Pharmabiz

Medtronic announces positive real-world registry results for Affera Mapping and Ablation System with the Sphere-9 Catheter and the PFA System

Medtronic announces positive real-world registry results for Affera Mapping and Ablation System with the Sphere-9 Catheter and the PFA System: Galway, Ireland Saturday, October 24 ...
Pharmabiz

Gilead to acquire investigational oral IL-23R inhibitor HCXT-2001 from PepStar Therapeutics for $1.275 billion

Gilead to acquire investigational oral IL-23R inhibitor HCXT-2001 from PepStar Therapeutics for $1.275 billion: Foster City, California Saturday, October 24, 2026, 10:00 Hrs [IST] ...
Pharmabiz

Labcorp, US FDA and Charles River announce research collaboration to advance preclinical methods for evaluating drug abuse potential

Labcorp, US FDA and Charles River announce research collaboration to advance preclinical methods for evaluating drug abuse potential: Burlington, North Carolina Saturday, October ...
Pharmabiz

Merck & Moderna to present positive results from phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda at ESMO 2026 Presidential Symposium

Merck & Moderna to present positive results from phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda at ESMO 2026 Presidential Symposium: Rahway, New Jersey Saturday ...
Pharmabiz

Otsuka presents final phase 3 VISIONARY results at ASN demonstrating Voyxact stabilized kidney function and reduced risk of disease progression and kidney failure

Otsuka presents final phase 3 VISIONARY results at ASN demonstrating Voyxact stabilized kidney function and reduced risk of disease progression and kidney failure: Princeton, New ...
Pharmabiz

Corporate oncology care faces margin squeeze as NPPA brings direct hospital supplies under 30% TMR net

Corporate oncology care faces margin squeeze as NPPA brings direct hospital supplies under 30% TMR net: Peethaambaran Kunnathoor, Chennai Saturday, October 24, 2026, 08:00 Hrs [IS ...
Pharmabiz

Indian healthcare sees med-tech innovation as a key driver of transformation with nationwide reach

Indian healthcare sees med-tech innovation as a key driver of transformation with nationwide reach: Nandita Vijayasimha, Bengaluru Saturday, October 24, 2026, 08:00 Hrs [IST] Indi ...
Pharmabiz

China approves Enhertu as first and only tumour agnostic HER2 directed medicine and ADC for previously treated patients with HER2 positive metastatic solid tumours

China approves Enhertu as first and only tumour agnostic HER2 directed medicine and ADC for previously treated patients with HER2 positive metastatic solid tumours: Tokyo Saturday ...